Orange Book Blog: House Energy and Commerce Committee to Hold Hearings on Follow-on Biologics and Reverse Payments: "On Wednesday, May 2nd, two subcommittees of the House Committee on Energy and Commerce will hold hearings of importance to pharmaceutical companies: first, on legislation to establish an abbreviated pathway for FDA approval of follow-on biologics; second, on a pending bill to ban 'reverse payment' settlements of Hatch-Waxman litigation.
At 10 a.m. ET, the Subcommittee on Health will hold a hearing entitled 'Assessing the Impact of a Safe and Equitable Biosimilar Policy in the United States.' Persons scheduled to appear include Dr. Janet Woodcock, Deputy Commissioner and Chief Medical Officer of the FDA, as well as executives from Insmed, Genentech, GPhA, and others.
At 3 p.m. ET, the Subcommittee on Commerce, Trade, and Consumer Protection will hold a hearing entitled 'Protecting Consumer Access to Generic Drugs Act of 2007.' Persons scheduled to appear include Jon Leibowitz, Commissioner of the FTC, as well as Prof. Scott Hemphill, law professor at Columbia, Dr. Barry Sherman, CEO of Apotex, and others."
